TITAN PHARMACEUTICALS INC (TTNP)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| General and administrative | 657 | 754 | 2,074 | |
| Total operating expenses | 657 | 754 | 2,074 | |
| Loss from operations | -657 | -754 | -2,074 | |
| Other nonoperating expense | - | - | 19 | |
| Other expense | -32 | -9 | - | |
| Interest income | - | - | - | |
| Other expense, net | -32 | -9 | -19 | |
| Net loss | -689 | -763 | -2,093 | |
| Basic net loss per common share | -0.65 | -0.83 | -2.29 | |
| Diluted net loss per common share | -0.65 | -0.83 | -2.29 | |
| Weighted average shares used in computing basic net loss per common share | 1,065,000 | 914,000 | 914,000 | |
| Weighted average shares used in computing diluted net loss per common share | 1,065,000 | 914,000 | 914,000 | |